Autobio Diagnostics Co (603658.SS) Stock Price

Autobio Diagnostics Co Price

SSE·CLOSED
38.72
​
Market closed

Over the last 14 years Autobio Diagnostics Co grew revenue by 23.8% annually, reaching 4.23 B CNY. Earnings per share have grown at 22.7% per year over the last 14 years. For Autobio Diagnostics Co, the net margin of 25.3% is broadly stable versus 25.9% a few years ago. At today's price the dividend yield works out to roughly 3.25%. The payout ratio is around 67% of earnings. The dividend has grown at 6.2% per year over the past 8 years. The consensus 12-month price target for Autobio Diagnostics Co is 47.45 CNY, about 22.5% above where the stock trades today. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus.

Autobio Diagnostics Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autobio Diagnostics Co business model & stock analysis

Autobio Diagnostics Co., Ltd. generates revenue through the sale of in vitro diagnostic reagents and instruments, including gnostic products, microbiology detection products, and related devices. The company's immunodiagnostic products consist of microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. Microbiology detection products feature training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers, all distributed within domestic markets. The firm targets domestic healthcare providers and laboratories as primary buyers of its diagnostic reagents and instruments. Its core products serve clinical diagnostics needs for infectious disease testing, microbial identification, and immune response analysis. The company's product portfolio emphasizes domestic market distribution, with no mention of international sales channels or export activities. Autobio Diagnostics' revenue streams are derived from the manufacturing and distribution of diagnostic reagents, instruments, and related devices. The company focuses on domestic market penetration through its product range, which includes specialized reagents for microbiology and immunodiagnosis. No additional revenue sources such as service contracts or software licensing are indicated in the business description.

Frequently asked questions about Autobio Diagnostics Co

Analysts currently set an average price target of 44.85 CNY for the Autobio Diagnostics Co stock (median: 47.45 CNY), implying +15.8 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Autobio Diagnostics Co stock: 8 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Autobio Diagnostics Co to generate revenue of 4.43 B CNY and earnings per share of 1.95 CNY.

Converted at the current exchange rate, the Autobio Diagnostics Co share trades at 5.28 EUR (38.72 CNY).

The Autobio Diagnostics Co share (603658.SS) is listed on 1 stock exchanges, including: Shanghai (603658.SS).

The expected revenue of Autobio Diagnostics Co is 4.43 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Autobio Diagnostics Co is 1.11 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Autobio Diagnostics Co is currently 19.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Autobio Diagnostics Co stock.

The price-to-sales ratio (P/S) of Autobio Diagnostics Co is currently 4.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Autobio Diagnostics Co stock.

The Eulerpool Quality Score for Autobio Diagnostics Co is 5/10.

The ISIN of Autobio Diagnostics Co is CNE100002GC4. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Autobio Diagnostics Co is 603658.SS. The ticker symbol is used to trade Autobio Diagnostics Co shares on the stock exchange.

Fair ValueTerminal
38.72 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
767,740.78 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Sep 1, 2016
ISIN
CNE100002GC4
Cusip
Y0483B104
Market capitalization
22.34 B CNYLarge Cap
52-Week Range
PEG
2.14
P/E ratio
P/Ee 2026
20.07
P/Ee 2027
17.67
P/Ee 2028
15.21
P/S
P/Se
4.99
EV/EBIT
19.36
P/B Ratio
2.50
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
11.97 %
Dividend
Dividend yield
3.25 %
Est. Dividend Yield
3.38 %
Payout Ratio
67.41 %
Dividend growth Ø5Y
12.72 %
Dividend payments per year
1
Dividend paid since
9 years
Dividend not reduced since
4 years
Dividend increased since
4 years
Dividend withholding tax
10.00 %
Last updated Nov 19, 2026, 3:41 AM

Autobio Diagnostics Co Peer Group

Autobio Diagnostics Co Ticker

SHH · 603658.SS

Autobio Diagnostics Co FIGI

603658:CH · BBG006MJLX77603658:CG · BBG006MJLX86603658:C1 · BBG00GVXBSG6